Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
02:13am, Wednesday, 06'th Aug 2025
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.
Wegovy maker Novo Nordisk's sales hike in second quarter
02:01am, Wednesday, 06'th Aug 2025
Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk sales rise 18% in second quarter
01:36am, Wednesday, 06'th Aug 2025
Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion
Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025
Novo Nordisk's weight loss challenge in five charts
01:04am, Wednesday, 06'th Aug 2025
Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy.
Investor Alert: Robbins LLP Informs Investors of the Novo Nordisk A/S Class Action Lawsuit
10:07pm, Tuesday, 05'th Aug 2025
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (NYSE: NVO) sec
Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now.
05:58pm, Tuesday, 05'th Aug 2025
The drugmaker is slated to report its second-quarter financial results early Wednesday.
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
05:06pm, Tuesday, 05'th Aug 2025
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/S
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Novo Nordisk expands legal action to protect patients from non-FDA approved weight-loss drugs
03:21pm, Tuesday, 05'th Aug 2025
CNBC's Brandon Gomez and Angelica Peebles join 'Power Lunch' to break down the biggest headlines in the pharmaceutical space.
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
03:16pm, Tuesday, 05'th Aug 2025
PHILADELPHIA , Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global ph
Novo Nordisk expands lawsuits against weight-loss drug compounders
03:04pm, Tuesday, 05'th Aug 2025
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss a
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: N
Why Novo Nordisk Stock Is Down Again Today
01:22pm, Tuesday, 05'th Aug 2025
Shares of Novo Nordisk (NVO -3.13%), the Danish pharmaceuticals company famed for its Ozempic and Wegovy weight loss drugs, collapsed after reporting earnings a week ago -- and it's been mostly a down
